Consistent with the above-mentioned mechanism findings that UBE2T promotes GC progression via Wnt/β-catenin signaling activation, it is attractive to develop inhibitors targeting cancer-specific Wnt/β-catenin signaling regulator UBE2T for GC therapy. The gene discussed is UBE2T; the disease is cancer.